NASDAQ:CTXR Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis $0.57 +0.01 (+1.99%) Closing price 11/3/2026 04:00 PM EasternExtended Trading$0.54 -0.04 (-6.14%) As of 05:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Citius Pharmaceuticals Stock (NASDAQ:CTXR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Citius Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.52▼$0.5750-Day Range$0.37▼$0.6352-Week Range$0.37▼$1.54Volume98,272 shsAverage Volume286,465 shsMarket Capitalization$15.73 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for critical care, oncology and other areas with significant unmet medical needs. The company is headquartered in Cranford, New Jersey, and has primarily focused its development and commercialization activities on the U.S. healthcare market. Citius’ lead product candidate has been Mino-Lok, an antibiotic lock solution designed to help salvage infected central venous catheters by treating catheter-related bloodstream infections while allowing the catheter to remain in place. The company has also pursued additional product opportunities, including therapies for oncology and other specialized conditions. Through its Citius Oncology subsidiary, the company has been associated with LYMPHIR (denileukin diftitox-cxdl), an immunotherapy approved by the U.S. Food and Drug Administration for certain adults with relapsed or refractory cutaneous T-cell lymphoma. Citius Pharmaceuticals is led by Chairman and Chief Executive Officer Leonard Mazur and continues to focus on advancing specialized pharmaceutical products through development, regulatory review and commercialization.AI Generated. May Contain Errors. Read More Citius Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreCTXR MarketRank™: 1.88346520048 of 5 starsCitius Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 684th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingCitius Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCitius Pharmaceuticals has a consensus price target of $6.00, representing about 946.8% upside from its current price of $0.57.Amount of Analyst CoverageCitius Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Citius Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($2.03) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Citius Pharmaceuticals is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Citius Pharmaceuticals is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCitius Pharmaceuticals has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Citius Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.85% of the float of Citius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCitius Pharmaceuticals has a short interest ratio ("days to cover") of 30.26, which indicates bearish sentiment.Change versus previous monthShort interest in Citius Pharmaceuticals has recently increased by 1.95%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCitius Pharmaceuticals does not currently pay a dividend.Dividend GrowthCitius Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Citius Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest2 people have searched for CTXR on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders4.99% of the stock of Citius Pharmaceuticals is held by insiders.Percentage Held by Institutions16.88% of the stock of Citius Pharmaceuticals is held by institutions.Read more about Citius Pharmaceuticals' insider trading history. Receive CTXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTXR Stock News HeadlinesCitius Pharmaceuticals, Inc. (CTXR) - What Are Brokerages Saying About This Stock?November 2 at 3:16 AM | americanbankingnews.comCitius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026October 26, 2026 | prnewswire.comLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.November 4 at 1:00 AM | Profits Run (Ad)Citius Pharmaceuticals to Participate in October 2026 Investor ConferencesOctober 12, 2026 | prnewswire.comCitius Pharmaceuticals to Participate in September 2026 Investor ConferencesSeptember 3, 2026 | prnewswire.comCitius Pharmaceuticals Receives Nasdaq Extension to Regain ComplianceAugust 22, 2026 | theglobeandmail.comCitius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | prnewswire.comSee More Headlines CTXR Stock Analysis - Frequently Asked Questions How have CTXR shares performed this year? Citius Pharmaceuticals' stock was trading at $0.7770 at the beginning of the year. Since then, CTXR shares have decreased by 26.2% and is now trading at $0.5732. How were Citius Pharmaceuticals' earnings last quarter? Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.02. When did Citius Pharmaceuticals' stock split? Shares of Citius Pharmaceuticals reverse split before market open on Tuesday, November 26th 2024.The 1-25 reverse split was announced on Friday, November 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Citius Pharmaceuticals? Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Citius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Pharmaceuticals investors own include NVIDIA (NVDA), NIO (NIO), Advanced Micro Devices (AMD), Tesla (TSLA), Bionano Genomics (BNGO), Palantir Technologies (PLTR) and Energy Transfer (ET). Company Calendar Last Earnings8/14/2026Today11/04/2026Next Earnings (Estimated)12/29/2026Fiscal Year End9/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CTXR's financial health is in the Red zone, according to TradeSmith. CTXR has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CTXR CIK1506251 Webwww.citiuspharma.com Phone(908) 967-6677FaxN/AEmployees23Year Founded2007Price Target and Rating Average Price Target for Citius Pharmaceuticals$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+946.8%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.43 million Net MarginsN/A Pretax Margin-816.00% Return on Equity-59.57% Return on Assets-34.47% Debt Debt-to-Equity Ratio0.08 Current Ratio0.84 Quick Ratio0.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.29 per share Price / Book0.13Miscellaneous Outstanding Shares27,450,000Free Float26,083,000Market Cap$15.73 million OptionableOptionable Beta1.05 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CTXR) was last updated on 11/3/2026 by MarketBeat.com Staff. From Our PartnersFinancial Legend: “Big trouble ahead …”Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution ri...Weiss Ratings | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredDr. Ron Paul: “It’s time to prepare”The Pentagon has plans for military bases to survive a 90-day disaster. A former Defense Intelligence Agency s...Stansberry Research | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
